Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Defining Genetic, Polygenic and Environmental Risk for Alzheimer’s Disease using multiple powerful cohorts, focussed Epigenetics and Stem cell metabolomics

PERADES

The PERADES Programme (Defining Genetic, Polygenic and Environmental Risk for Alzheimer’s Disease, using multiple powerful cohorts, focussed Epigenetics and Stem cell metabolomics) will find new susceptibility genes for early and late-onset Alzheimer’s disease. It will take all genetic findings and test for relationships with life- style...

Funding Programme
Start Date
End Date
Total Funding
€ 3 171 567
European Countries Involved

Dementia Ambient Care: Multi-Sensing Monitoring for Intelligent Remote Management and Decision Support

Dem@Care

The increase in average lifespan across the world has been accompanied by an unprecedented upsurge in the occurrence of dementia with high socio-economic costs. The development of personal health systems provides a means of dealing with such problems in a meaningful and sustainable manner, enabling persons with dementia to maintain independence and...

Funding Programme
Start Date
End Date
Total Funding
€ 10 626 393
European Countries Involved

Dementia: Intersectorial Strategy for Training and Innovation Network for Current Technology (DISTINCT)

DISTINCT

The main aim of DISTINCT will develop a premier quality multi-disciplinary, multi-professional and intersectorial education and training research framework for Europe aimed at improving technology and care for people with dementia and their carers, and to use coherent themes an.d interrelated ESRs within DISTINCT to provide the evidence to show how...

Funding Programme
Start Date
End Date
Total Funding
€ 3 998 048
European Countries Involved

Designing for People with Dementia: designing for mindful self-empowerment and social engagement

MinD

This project aims to help people with dementia engage in social contexts to improve psychosocial wellbeing. People who are affected by Alzheimer’s disease or other dementias often face cognitive, behavioural and psychosocial difficulties, including impairment and degeneration of memory and of perceptions of identity. In a social context, this can...

Funding Programme
Start Date
End Date
Total Funding
€ 549 000
European Countries Involved

Development of a Novel Multicellular In Vitro Model of Alzheimer’s disease-like Blood-Brain Barrier

NAB3

A striking challenge in diagnosis and therapy of neurodegenerative diseases is the design of drugs capable of crossing the blood-brain barrier (BBB), a tightly regulated barrier that prevents the passage of drugs from the blood to the brain. In vitro cellular BBB models are available, but they mimic only healthy conditions without taking into...

Funding Programme
Start Date
End Date
Total Funding
€ 812 488
European Countries Involved

Devising a personalized risk stratification and holistic management for prevention of cognitive impairment in patients with different cardiovascular phenotypes

DORIAN GRAY

DORIAN GRAY project investigates the link between cardiovascular disease (CVD) and Mild Cognitive Impairment (MCI) in the ageing population. Its goal is to uncover underlying mechanisms to promote healthy, independent, and active living while reducing disease burden. Aligned with EU-Horizon Europe’s Strategic Plan on NCDs prevention, the project...

Funding Programme
Start Date
End Date
Total Funding
€ 10 921 114

Diagnostic and prognostic precision medicine for behavioral variant frontotemporal dementia

DIPPA-FTD

The behavioural variant of frontotemporal dementia (bvFTD) is a common cause of early-onset dementia that presents with changes in behavior and personality. It is often misdiagnosed and mistaken for a psychiatric disorder, such as depression or bipolar disorder. Unlike with Alzheimer’s disease, we still lack reliable tests that enable a diagnosis...

Funding Programme
Start Date
End Date
Total Funding
€ 1 320 000
European Countries Involved

Dissecting Brain Pollutant Exposure and its Contribution to Neurodegeneration and Alzheimer’s disease: From Signatures to Prevention Strategies to Protect and Maintain a Healthy Brain

EXPOSIGNALZ

Human populations are impregnated by various types of chemical pollutants reported as hazardous waste present in the environment. Certain pollutants have adverse effects on brain, but the underlying mechanisms and time-window exposures are still unknown, as well as their contribution on dementia, the 7th leading cause of death. EXPOSIGNALZ project...

Funding Programme
Start Date
End Date
Total Funding
€ 930 987 982
European Countries Involved

DNA Damage and Repair and its Impact on Healthy Ageing

Dam2Age

We pioneered an initially highly controversial connection between DNA damage and (accelerated) aging. In the previous ERC grant ‘DamAge’ we reached the stage that (segmental) aging in DNA repair-deficient mice can be largely controlled. The severity of the repair defect determines the rate of segmental aging; the repair pathways affected influence...

Funding Programme
Start Date
End Date
Total Funding
€ 2 251 719
European Countries Involved

DNA rEpair impaired Mice with accElerated Neurodegeneration as Tool to Improve Alzheimer therapeutics

Dementia

Alzheimer’s disease (AD) affects worldwide ~50 million people. Preclinical research relies mainly on transgenic mouse models overexpressing mutant human proteins that are altered in <5% of AD cases (e.g. β-amyloid and tau), however, despite prominent protein aggregates, they fail to show the dramatic neurodegeneration and cognitive decline of patients, indicating that plaques and tangles may not be the only requirement for AD. Age is the most determining factor in AD, but is poorly represented in current AD models.
Generating bona fide mouse models for various human DNA repair syndromes we have disclosed a very strong connection between DNA damage, repair and aging including dramatic neurodegeneration. Within the context of ERC-DamAge we discovered striking parallels in neurodegeneration, progressive cognitive decline and genome-wide expression profiles of repair-deficient Ercc1Δ/- mice and human AD. The similarities in expression profiles are an order of magnitude higher than current AD mouse models. We discovered that nutritional interventions can spectacularly delay neurodegeneration, opening realistic perspectives for combating AD and other neurodegenerative disorders. The primary goal of this application is to complete the characterization of the mouse mutants as a valid model for AD by a detailed quantitative comparison of all RNA classes of relevant brain compartments of Ercc1Δ/- mutants and AD patients. This not only provides the final PoC, but also an unparalleled resource for pathway analysis, target identification and biomarkers for monitoring disease progression and effects of any intervention. This application will be instrumental to facilitate transition to a valid AD model for pharmaceutical companies enabling development of effective medication for prevention and/or therapy. This proposal addresses a huge unmet medical need worldwide, which seriously affects QoL, challenges health care systems, and offers unprecedented socio-economical opportunities.

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Doctoral training network TAu imMunE: strategies for innovative diagnosis and therapies in dementia

TAME

There is an urgent medical need for efficient diagnostics for Alzheimer’s disease and related tauopathies, as well as disease modifying treatments, due to the heavy burden of the disease on patients, families and society. To address this public health issue, TAME R&I training network gathers leading academic and industrial experts in tau research...

Funding Programme
Start Date
End Date
Total Funding
€ 2 431 389
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).